Bangalore: South African-based subsidiary of Mylan Laboratories, a leading manufacturer of antiretroviral (ARV) drugs, has been selected as an ARV supplier by the South African National Department of Health for the tender period from January 1, 2013-to-December 31, 2014.

Mylan secured a $127 million (R1.12 billion) share, which represents 19.1 percent of the $671 million (R5.9 billion) tender value. As a part of this award, Mylan will supply the South African Government with 31 percent of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender. Mylan is pleased to support the government's initiative to move to triple therapy FDC treatment regimens in South Africa, as such regimens can simplify treatment and improve patient adherence.

Mylan CEO Ms Heather Bresch commented, "Mylan's mission is to provide the world's seven billion people access to high quality medicines, including affordable ARVs. Only through access to these vital medicines can we stem the tide of HIV/AIDS in South Africa and around the world. This award reinforces Mylan's commitment to provide high quality advanced drugs to help people suffering from HIV/AIDS in South Africa, and we are proud to have been selected as a partner to the South African Department of Health."

"We believe Mylan's selection as a leading supplier to the South African Government's ARV tender reflects our vertical integration, quality manufacturing, global scale and proven-track record of being a reliable partner in supplying affordable ARV medicines across the world. We are pleased to bring this global scale, quality and reliability to the South African market and continue our legacy in fighting HIV/AIDS," said Mr Paul Miller, managing director and vice president of Mylan's South African business.

Mylan supplies ARV drugs to more than 120 countries around the world and approximately one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product. Mylan will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.